Ryan Moslin

Highly Selective Inhibition of Tyrosine Kinase 2 (TYK2) for the Treatment of Autoimmune Diseases: Discovery of the Allosteric Inhibitor BMS-986165

Stephen T. Wrobleski, Ryan Moslin, Shuqun Lin et al. · Journal of Medicinal Chemistry · 2019 · 369 citations · Full text

Pharmacy, Medicinal Chemistry, Pharmacology +15

Autoimmune pathways in mice and humans are blocked by pharmacological stabilization of the TYK2 pseudokinase domain

James R. Burke, Lihong Cheng, Kathleen M. Gillooly et al. · Science Translational Medicine · 2019 · 282 citations

Life Sciences, Immunology, Pharmacology +14

Identification of <i>N</i>-Methyl Nicotinamide and <i>N</i>-Methyl Pyridazine-3-Carboxamide Pseudokinase Domain Ligands as Highly Selective Allosteric Inhibitors of Tyrosine Kinase 2 (TYK2)

Ryan Moslin, Yanlei Zhang, Stephen T. Wrobleski et al. · Journal of Medicinal Chemistry · 2019 · 92 citations · Full text

Life Sciences, Medicinal Chemistry, Pharmacology +17

Identification of Imidazo[1,2-<i>b</i>]pyridazine Derivatives as Potent, Selective, and Orally Active Tyk2 JH2 Inhibitors

Chunjian Liu, James C. Lin, Ryan Moslin et al. · ACS Medicinal Chemistry Letters · 2019 · 53 citations · Full text

Pharmacy, Medicinal Chemistry, Pharmacology +12

Identification of imidazo[1,2-<i>b</i>]pyridazine TYK2 pseudokinase ligands as potent and selective allosteric inhibitors of TYK2 signalling

Ryan Moslin, Daniel S. Gardner, Joseph B. Santella et al. · MedChemComm · 2016 · 51 citations · Full text

Life Sciences, Immunology, Medicinal Chemistry +17